The Patent Finder
HT

Halia Therapeutics, Inc.

First filing 2021
OverviewNotableFeesChangesFamiliesPatent listSources & methods

Seven patents currently held, every record listed here

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in May 2041. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
May 2041
Next term end
3
Patent families

When these terms end

Each bar runs from grant to computed term end. 2021 to 2043.
US 11,161,852 Inhibitors of NEK7 Kinase May 7, 2041
US 11,713,321 Inhibitors of NEK7 Kinase May 7, 2041
US 12,091,413 Inhibitors of NEK7 Kinase no later than May 7, 2041
US 11,578,061 Inhibitors of LRRK2 Kinase Mar 23, 2042
US 11,866,423 Inhibitors of LRRK2 Kinase Mar 23, 2042
US 12,428,404 Inhibitors of LRRK2 Kinase Mar 23, 2042
US 12,709,616 NEK7 Inhibitors Apr 19, 2043
20262031203620412043
A dotted end marks a recorded terminal disclaimer this site has not resolved: the term can only be shorter than the bar, never longer.
13 pending applications: term is not computable until grant.Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Feb 1, 2027
    The maintenance fee for Inhibitors of NEK7 Kinase (US 11,713,321) comes due Feb 1, 2027. Unpaid by Aug 2, 2027, it lapses early.
  • 1 fee due Jul 9, 2027
    The maintenance fee for Inhibitors of LRRK2 Kinase (US 11,866,423) comes due Jul 9, 2027. Unpaid by Jan 10, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

What they patent

Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
Inhibitors of LRRK2 Kinase3 in forceto Mar 2042
Inhibitors of NEK7 Kinase3 in forceto May 2041
NEK7 Inhibitors1 in forceto Apr 2043

Patents held now

Soonest term end first.

Showing 1 to 7 of 7

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatusExpiresConfidence
US 11,161,852Inhibitors of NEK7 Kinase
In force
 · High confidence
In forceHigh confidence
US 11,713,321Inhibitors of NEK7 Kinase
In force
 · High confidence
In forceHigh confidence
US 12,091,413Inhibitors of NEK7 Kinase
In force
 · Medium confidence
In forceMedium confidence
US 11,578,061Inhibitors of LRRK2 Kinase
In force
 · High confidence
In forceHigh confidence
US 11,866,423Inhibitors of LRRK2 Kinase
In force
 · High confidence
In forceHigh confidence
US 12,428,404Inhibitors of LRRK2 Kinase
In force
 · High confidence
In forceHigh confidence
US 12,709,616NEK7 Inhibitors
In force
 · High confidence
In forceHigh confidence
Also on record, not counted in the 7: 13 applications pending · 2 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited